Get access

Glutamate Cysteine Ligase Modifier (GCLM) Subunit Gene Is Not Associated with Methamphetamine-Use Disorder or Schizophrenia in the Japanese Population

Authors

  • Taro Kishi,

    1. Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
    Search for more papers by this author
  • Masashi Ikeda,

    1. Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
    Search for more papers by this author
  • Tsuyoshi Kitajima,

    1. Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
    Search for more papers by this author
  • Yoshio Yamanouchi,

    1. Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
    Search for more papers by this author
  • Yoko Kinoshita,

    1. Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
    Search for more papers by this author
  • Kunihiro Kawashima,

    1. Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
    Search for more papers by this author
  • Toshiya Inada,

    1. Department of Psychiatry, Teikyo University Ichihara Hospital, Ichihara, Japan
    2. Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
    Search for more papers by this author
  • Mutsuo Harano,

    1. Department of Neuropsychiatry, Kurume University Graduate School of Medicine, Kurume, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Tokutaro Komiyama,

    1. Department of Psychiatry, Iida Hospital, Iida, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Toru Hori,

    1. Division of Psychiatry, National Center Hospital for Mental, Nervous and Muscular Disorders, National Center of Neurology and Psychiatry, Kodaira, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Mitsuhiko Yamada,

    1. Department of Psychogeriatrics, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Masaomi Iyo,

    1. Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Ichiro Sora,

    1. Department of Psychobiology, Tohoku University Graduate School of Medicine, Sendai, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Yoshimoto Sekine,

    1. Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, Hamamatsu, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Norio Ozaki,

    1. Department of Psychiatry and Psychobiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Hiroshi Ujike,

    1. Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author
  • Nakao Iwata

    1. Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
    2. Japanese Genetics Initiative for Drug Abuse (JGIDA)
    Search for more papers by this author

Address for correspondence: Taro Kishi, M.D., Ph.D., Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan. Voice: +81-562-93-9250; fax: +81-562-93-1831. taroh@fujita-hu.ac.jp

Abstract

A recent study showed a significant association between schizophrenia in European samples and the glutamate cysteine ligase modifier (GCLM) subunit gene, which is the key glutathione (GSH)-synthesizing enzyme. Since the symptoms of methamphetamine (METH)-induced psychosis are similar to those of schizophrenia, the GCLM gene is thought to be a good candidate gene for METH-use disorder or related disorders. To evaluate the association between the GCLM gene and METH-use disorder and schizophrenia, we conducted a case-control study of Japanese subjects (METH-use disorder, 185 cases; schizophrenia, 742 cases; and controls, 819). Four SNPs (2 SNPs from an original report and JSNP database, and 2 “tagging SNPs” from HapMap database) in the GCLM gene were examined in this association analysis; one SNP showed an association with both METH-use disorder and METH-induced psychosis. After Bonferroni's correction for multiple testing, however, this significance disappeared. No significant association was found with schizophrenia. Our findings suggest that a common genetic variation in the GCLM gene might not contribute to the risk of METH-use disorder and schizophrenia in the Japanese population.

Ancillary